首页> 外文期刊>Radiology Research and Practice >Whole Body Microwave Irradiation for Improved Dacarbazine Therapeutical Action in Cutaneous Melanoma Mouse Model
【24h】

Whole Body Microwave Irradiation for Improved Dacarbazine Therapeutical Action in Cutaneous Melanoma Mouse Model

机译:全身微波辐照改善达卡巴嗪在皮肤黑色素瘤小鼠模型中的治疗作用

获取原文
       

摘要

A cutaneous melanoma mouse model was used to test the efficacy of a new therapeutical approach that uses low doses of cytostatics in conjunction with mild whole body microwave exposure of 2.45 GHz in order to enhance cytostatics antitumoral effect.Materials and Methods.A microwave exposure system for C57BL/6 mouse whole body microwave irradiation was designed; groups of 40 mice (males and females) bearing experimental tumours were subjected to a combined therapy comprising low doses of dacarbazine in combination with mild whole body irradiation. Clinical parameters and serum cytokine testing using xMAP technology were performed.Results.The group that was subjected to combined therapy, microwave and cytostatic, had the best clinical evolution in terms of overall survival, tumour volume, and metastatic potential. At day 14 the untreated group had 100% mortality, while in the combined therapy group 40% of mice were surviving. Quantifying serum IL-1β, IL-6, IL-10, IL-12 (p70), IFN-γ, GM-CSF, TNF-α, MIP-1α, MCP-1, and KC during tumorigenesis and therapy found that the combined experimental therapy decreases all the inflammatory cytokines, except chemokine MCP-1 that was found increased, suggesting an increase of the anti-tumoral immune response triggered by the combined therapy. The overall metastatic process is decreased in the combined therapy group.
机译:皮肤黑素瘤小鼠模型用于测试一种新的治疗方法的功效,该方法使用低剂量的细胞生长抑制剂和2.45 GHz的轻度全身微波照射,以增强细胞生长抑制剂的抗肿瘤作用。材料和方法。设计了C57BL / 6小鼠全身微波辐射;每组40只患有实验性肿瘤的小鼠(雄性和雌性)接受联合治疗,包括低剂量达卡巴嗪与温和的全身照射。结果:采用微波和细胞抑制疗法联合治疗的组在总生存率,肿瘤体积和转移潜力方面具有最佳的临床进展。在第14天,未治疗组的死亡率为100%,而在联合治疗组中,有40%的小鼠存活。在肿瘤发生和治疗过程中对血清IL-1β,IL-6,IL-10,IL-12(p70),IFN-γ,GM-CSF,TNF-α,MIP-1α,MCP-1和KC进行定量检测发现联合实验疗法可降低所有炎症细胞因子,但已发现趋化因子MCP-1升高除外,这提示联合疗法触发的抗肿瘤免疫应答增加。联合治疗组的总转移过程减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号